Patients with testicular cancer receiving adjuvant chemotherapy: Compliance with follow-up in the first three years

Abstract

PurposeThe aim of this study was to investigate the compliance with follow-up in patients receiving adjuvant chemotherapy (ACT) for testicular cancer at two academic hospitals. Materials and methodsThe study analyzed 104 patients with testicular tumors who had undergone surgery at least a year before and received ACT between March 2017 to March 2022. The mean follow-up was 29.2±16.2 (12–73) months. Patients were classified as fully compliant (100% compliance), moderately compliant (50–99%), poorly compliant (1–49%), and non-compliant (no attendance) according to their compliance with the follow-up schedule. ResultsAt the end of the first year, 76% of patients were fully compliant. By the end of the second year, this number dropped to 50%. Furthermore, 25% of patients were identified as non-compliant in the second year and only 4.3% in the third year. When comparing patients who were compliant and non-compliant at first- and second-year follow-up, no statistically significant difference was found according to age, tumor size, disease stage, or ACT regimen (P=0.938, P=0.784, P=0.867, and P=0.282, respectively). ConclusionThis study showed that full compliance with follow-up gradually decreased over the years and that the factors examined were not able to predict this decrease. Prospective studies can help design individualized education and follow-up programs, considering each patient's tumor stage. Level of evidence3.